Advertisement

Molecular Medicine

, Volume 20, Issue 1, pp 625–638 | Cite as

Deletion of STAT5a/b in Vascular Smooth Muscle Abrogates the Male Bias in Hypoxic Pulmonary Hypertension in Mice: Implications in the Human Disease

  • Yang-Ming Yang
  • Huijuan Yuan
  • John G. Edwards
  • Yester Skayian
  • Kanta Ochani
  • Edmund J. Miller
  • Pravin B. Sehgal
Research Article

Abstract

Chronic hypoxia typically elicits pulmonary hypertension (PH) in mice with a male-dominant phenotype. There is an opposite-sex bias in human PH, with a higher prevalence in women, but greater survival (the “estrogen paradox”). We investigated the involvement of the STAT5a/b species, previously established to mediate sexual dimorphism in other contexts, in the sex bias in PH. Mice with heterozygous or homozygous deletions of the STAT5a/b locus in vascular smooth muscle cells (SMCs) were generated in crosses between STAT5a/bfl/fl and transgelin (SM22α)-Cre+/+ parents. Wild-type (wt) males subjected to chronic hypoxia showed significant PH and pulmonary arterial remodeling, with wt females showing minimal changes (a male-dominant phenotype). However, in conditional STAT5+/− or STAT5−/− mice, hypoxic females showed the severest manifestations of PH (a female-dominant phenotype). Immunofluorescence studies on human lung sections showed that obliterative pulmonary arterial lesions in patients with idiopathic pulmonary arterial hypertension (IPAH) or hereditary pulmonary arterial hypertension (HPAH), both male and female, overall had reduced STAT5a/b, reduced PY-STAT5 and reduced endoplasmic reticulum (ER) GTPase atlastin-3 (ATL3). Studies of SMCs and endothelial cell (EC) lines derived from vessels isolated from lungs of male and female IPAH patients and controls revealed instances of coordinate reductions in STAT5a, STAT5b and ATL3 in IPAH-derived cells, including SMCs and ECs from the same patient. Taken together, these data provide the first definitive evidence for a contribution of STAT5a/b to the sex bias in PH in the hypoxic mouse and implicate reduced STAT5 in the pathogenesis of the human disease.

Notes

Acknowledgments

We thank Lothar Hennighausen (National Institute of Diabetes, Digestive and Kidney Diseases, Bethesda, MD, USA) for a breeder pair of the STAT5a/bfl/fl mice and Rubin M Tuder (University of Colorado-Denver, Aurora, CO, USA) for the human lung sections (controls and IPAH). Additional lung sections, SMCs and ECs derived from lungs of male and female IPAH patients and controls were provided under the PHBI from the Baylor College of Medicine, The Cleveland Clinic Foundation, University of Alabama at Birmingham, Stanford University, Vanderbilt University, University of California at San Diego, Duke University, University of Michigan, University of Colorado-Denver, Allegheny General Hospital, and University of Pennsylvania. Funding for PHBI is provided by the Cardiovascular Medical Research and Education Fund (CMREF). This work was supported in part by National Heart, Lung, and Blood Institute Grants HL-087176 (to PB Sehgal), HL-114509 (to PB Sehgal) and HL-111469 (EJ Miller).

Supplementary material

10020_2014_2001625_MOESM1_ESM.pdf (4.9 mb)
Supplementary material, approximately 4424 KB.

References

  1. 1.
    Austin ED, et al. (2009) Alterations in oestrogen metabolism: implications for higher penetrance of familial pulmonary arterial hypertension in females. Eur. Respir. J. 34:1093–9.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Austin ED, et al. (2013) Gender, sex hormones and pulmonary hypertension. Pulm. Circ. 3:294–314.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Dempsie Y, MacLean MR. (2013) The influence of gender on the development of pulmonary arterial hypertension. Exp. Physiol. 98:1257–61.CrossRefPubMedGoogle Scholar
  4. 4.
    Lahm T, Tuder RM, Petrache I. (2014) Progress in solving the sex hormone paradox in pulmonary hypertension. Am. J. Physiol Lung Cell Mol Physiol. 307:L7–26.CrossRefPubMedGoogle Scholar
  5. 5.
    Umar S, Rabinovitch M, Eghbali M. (2012) Estrogen paradox in pulmonary hypertension: current controversies and future perspectives. Am. J. Respir. Crit. Care Med. 186:125–31.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Fessel JP, Loyd JE, Austin ED. (2011) The genetics of pulmonary arterial hypertension in the post-BMPR2 era. Pulm. Circ. 1:305–19.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    White K, et al. (2011) The serotonin transporter, gender, and 17beta oestradiol in the development of pulmonary arterial hypertension. Cardiovasc. Res. 90:373–82.CrossRefPubMedGoogle Scholar
  8. 8.
    White K, et al. (2012) Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension. Circulation. 126:1087–98.CrossRefPubMedGoogle Scholar
  9. 9.
    Rabinovitch M, Gamble WJ, Miettingen OS, Reid L. (1981) Age and sex influence on pulmonary hypertension of chronic hypoxia and recovery. Am. J. Physiol. Heart Circ. Physiol. 240:H62–72.CrossRefGoogle Scholar
  10. 10.
    Resta TC, Kanagy NL, Walker BR. (2001) Estradiol-induced attenuation of pulmonary hypertension is not associated with altered eNOS expression. Am. J. Physiol. Lung Cell Mol. Physiol. 280:L88–97.CrossRefPubMedGoogle Scholar
  11. 11.
    Smith P, Moosavi H, Winson M, Heath D. (1974) The influence of age and sex on the response of the right ventricle, pulmonary vasculature and carotid bodies to hypoxia in rats. J. Path. 112:11–8.CrossRefPubMedGoogle Scholar
  12. 12.
    Stenmark KR, Fagan KA, Frid MG. (2006) Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ. Res. 99:675–91.CrossRefPubMedGoogle Scholar
  13. 13.
    Coutant R, Lahlou N, Bouvattier C, Bougneres P. (1998) Circulating leptin level and growth hormone response to stimulation in obese and normal children. Eur. J. Endocrin. 139:591–7.CrossRefGoogle Scholar
  14. 14.
    Gebert CA, Park SH, Waxman DJ. (1997) Regulation of signal transducer and activator of transcription (STAT) 5b activation by the temporal pattern of growth hormone stimulation. Mol. Endocrinol. 11:400–14.CrossRefPubMedGoogle Scholar
  15. 15.
    Holloway MG, et al. (2007) Loss of sexually dimorphic liver gene expression upon hepatocyte-specific deletion of Stat5a-Stat5b locus. Endocrinology. 148:1977–86.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Low MJ, et al. (2001) Somatostatin is required for masculinization of growth hormone-regulated hepatic gene expression but not of somatic growth. J. Clin. Invest. 107:1571–80.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Meyer RD, Laz EV, Su T, Waxman DJ. (2009) Male-specific hepatic Bcl6: growth hormone-induced block of transcription elongation in females and binding to target genes inversely coordinated with STAT5. Mol. Endocrin. 23:1914–26.CrossRefGoogle Scholar
  18. 18.
    Nishida Y, Yoshioka M, St. Amand J. (2005) Sexually dimorphic gene expression in the hypothalamus, pituitary gland, and cortex. Genomics. 85:679–87.CrossRefGoogle Scholar
  19. 19.
    Sugathan A, Waxman DJ. (2013) Genome-wide analysis of chromatin states reveals distinct mechanisms of sex-dependent gene regulation in male and female mouse liver. Mol. Cell. Biol. 33:3594–610.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tannenbaum GS, Choi HK, Gurd W, Waxman DJ. (2001) Temporal relationship between the sexually dimorphic spontaneous GH secretory profiles and hepatic STAT5 activity. Endocrinology. 142:4599–606.CrossRefPubMedGoogle Scholar
  21. 21.
    Thangavel C, Shapiro BH. (2007) A molecular basis for the sexually dimorphic response to growth hormone. Endocrinology. 148:2894–903.CrossRefPubMedGoogle Scholar
  22. 22.
    Udy GB, et al. (1997) Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. Proc. Natl. Acad. Sci. U. S. A. 94:7239–44.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Waxman DJ, Ram PA, Park SH, Choi HK. (1995) Intermittent plasma growth hormone triggers tyrosine phosphorylation and nuclear translocation of a liver-expressed, Stat 5-related DNA binding protein: Proposed role as an intracellular regulator of male-specific liver gene transcription. J. Biol. Chem. 27:13262–70.CrossRefGoogle Scholar
  24. 24.
    Zhang Y, Laz EV, Waxman DJ. (2012) Dynamic, sex-differential STAT5 and BCL6 binding to sex-biased, growth hormone-regulated genes in adult mouse liver. Mol. Cell Biol. 32:880–96.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Cui Y, et al. (2004) Inactivation of Stat5 in mouse mammary epithelium during pregnancy reveals distinct functions in cell proliferation, survival, and differentiation. Mol. Cell Biol. 24:8037–47.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hennighausen L, Robinson GW. (2008) Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev. 22:711–21.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Hosui A, et al. (2009) Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-β and STAT3 activation. J. Exp. Med. 206:819–31.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Stark GR, Darnell JE Jr. (2012) The JAK-STAT pathway at twenty. Immunity. 36:503–14.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Basso K, et al. (2010) Integrated biochemical and computational approach identifies BCL-6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood. 115:975–84.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Chen J, Wang M, Guo M, Xie Y, Cong YS. (2013) miR-127 regulates cell proliferation and senescence by targeting Bcl6. PLoS One. 8:e80266.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Conforto TL, Zhang Y, Sherman J, Waxman DJ. (2012) Impact of CUX2 on the female mouse liver transcriptome: activation of female-biased genes and repression of male-biased genes. Mol. Cell. Biol. 32:4611–27.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM. (1997) Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science. 276:589–92.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Nazari-Jahantigh M, et al. (2012) MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J. Clin. Invest. 122:4190–202.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Sawant DV, Wu H, Kaplan MH, Dent AL. (2013) The Bcl6 target gene microRNA-21 promotes Th2 differentiation by a T cell intrinsic pathway. Mol. Immunol. 54:435–42.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    MacLeod JN, Pampori NA, Shapiro BH. (1991) Sex differences in the ultradian pattern of plasma growth hormone concentrations in mice. J Endocrin. 131:395–399.CrossRefGoogle Scholar
  36. 36.
    Muller EE, Locatelli V, Cocchi D. (1999) Neuroendocrine control of growth hormone secretion. Physiol. Rev. 79:511–607.CrossRefPubMedGoogle Scholar
  37. 37.
    El Bizri N, et al. (2008) SM22alpha-targeted deletion of bone morphogenetic protein receptor 1A in mice impairs cardiac and vascular development, and influences organogenesis. Development. 135:2981–91.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Zhu BM, et al. (2008) Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression. Blood. 112:2071–80.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Zhang Y, et al. (2012) Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension. Mol. Med. 18:215–23.CrossRefGoogle Scholar
  40. 40.
    Ogura S, et al. (2013) Oxidative stress augments pulmonary hypertension in chronically hypoxic mice overexpressing the oxidized LDL receptor. Am. J. Physiol. Heart Circ. Physiol. 305:H155–62.CrossRefPubMedGoogle Scholar
  41. 41.
    Yang YM, Lane KB, Sehgal PB. (2013) Subcellular mechanism in pulmonary arterial hypertension: combinatorial modalities that inhibit anterograde trafficking and cause bone morphogenetic protein receptor 2 mislocalization. Pulm. Circ. 3:533–50.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Sehgal PB, et al. (2009) Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nefinfected macaques. Am. J. Physiol. Lung Cell Mol. Physiol. 297:L729–37.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Sehgal PB, Lee JE. (2011) Protein trafficking dysfunctions: role in the pathogenesis of pulmonary arterial hypertension. Pulm. Circ. 1:17–32.CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Sehgal PB. (2013) Non-genomic STAT5-dependent effects at the endoplasmic reticulum and Golgi apparatus and STAT6-GFP in mitochondria. JAX-STAT. 2:e24860.CrossRefGoogle Scholar
  45. 45.
    Lee JE, et al. (2012) Nongenomic STAT5-dependent effects on Golgi apparatus and endoplasmic reticulum structure and function. Am. J. Physiol. Cell Physiol. 302:C804–20.CrossRefPubMedGoogle Scholar
  46. 46.
    Lee JE, Yang YM, Yuan H, Sehgal PB. (2013) Definitive evidence using enucleated cytoplasts for a nongenomic basis for the cystic change in endoplasmic reticulum structure caused by STAT5a/b siRNAs. Am. J. Physiol. Cell Physiol. 304:C312–23.CrossRefPubMedGoogle Scholar
  47. 47.
    Choi HK, Waxman DJ. (1999) Growth hormone, but not prolactin, maintains low-level activation of STAT5a and STAT5b in female rat liver. Endocrinology. 140:5126–35.CrossRefPubMedGoogle Scholar
  48. 48.
    Liu X, Robinson GW, Gouilleux F, Groner B, Hennighausen L. (1995) Cloning and expression of Stat5 and an additional homologue (Stat5b) involved in prolactin signal transduction in mouse mammary tissue. Proc. Natl. Acad. Sci. U. S. A. 92:8831–5.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Ortiz BL, Sanchez-Gomez M, Norstedt G. (2000) Comparison of STAT5 mRNA levels in GH-treated male and female rats analyzed by a solution hybridization assay. Growth Horm. IGF. Res. 10:236–41.CrossRefPubMedGoogle Scholar
  50. 50.
    Smith P, Heath D. (1977) Ultrastructure of hypoxic hypertensive pulmonary vascular disease. J. Path. 121:93–100.CrossRefPubMedGoogle Scholar
  51. 51.
    Smith P, Heath D. (1979) Electron microscopy of the plexiform lesion. Thorax. 34:177–86.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Cao H, et al. (2006) Novel role for STAT-5B in the regulation of Hsp27-FGF-2 axis facilitating thrombin-induced vascular smooth muscle cell growth and motility. Circ. Res. 98:913–22.CrossRefPubMedGoogle Scholar
  53. 53.
    Cocolakis E, et al. (2008) Smad signaling antagonizes STAT5-mediated gene transcription and mammary epithelial cell differentiation. J. Biol. Chem. 283:1293–307.CrossRefPubMedGoogle Scholar
  54. 54.
    Pak SH, et al. (2012) Hypoxia upregulates Hsp90alpha expression via STAT5b in cancer cells. Int. J. Oncol. 41:161–8.PubMedGoogle Scholar
  55. 55.
    Toney LM, et al. (2000) BCL-6 regulates chemokine gene transcription in macrophages. Nat. Immunol. 1:214–20.CrossRefPubMedGoogle Scholar
  56. 56.
    Wang D, et al. (2008) BCL6 represses Smad signaling in transforming growth factor-beta resistance. Can. Res. 68:783–9.CrossRefGoogle Scholar
  57. 57.
    Arrigo T, Rulli I, Sferlazzas C, DeLuca F. (2003) Pubertal development in cystic fibrosis: an overview. J. Pediatr. Endocrinol. Metab. Suppl. 2:267–70.Google Scholar
  58. 58.
    Saint-Criq V, Harvey BJ. (2014) Estrogen and the cystic fibrosis gender gap. Steroids. 81:4–8.CrossRefPubMedGoogle Scholar
  59. 59.
    Wang Y, Cela E, Gagnon S, Sweezey NB. (2010) Estrogen aggravates inflammation in Pseudomonas aeriginosa pneumonia in cystic fibrosis mice. Respir. Res. 11:166.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Ciuclan L, et al. (2011) A novel murine model of severe pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 184:1171–82.CrossRefPubMedGoogle Scholar
  61. 61.
    Taraseviciene-Stewart L, et al. (2001) Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J. 15:427–38.CrossRefPubMedGoogle Scholar
  62. 62.
    Joung YH, et al. (2003) Hypoxia activates signal transducers and activators of transcription 5 (STAT5) and increases its binding activity to the GAS element in mammary epithelial cells. Exp. Mol. Med. 35:350–7.CrossRefPubMedGoogle Scholar
  63. 63.
    Joung YH, et al. (2005) Hypoxia activates the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer cells. Exp. Mol. Med. 37:353–64.CrossRefPubMedGoogle Scholar
  64. 64.
    Loges S, et al. (2006) Downregulation of VEGF-A, STAT5 and AKT in acute myeloid leukemia blasts of patients treated with SU5416. Leuk. Lymphoma. 47:2601–9.CrossRefPubMedGoogle Scholar
  65. 65.
    Yee KWH, et al. (2002) SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood. 100:2941–9.CrossRefPubMedGoogle Scholar
  66. 66.
    Harada T, et al. (2014) Decreased “ineffective erythropoiesis” preserves polycythemia in mice under long-term hypoxia. Clin. Exp. Med. Epub Jun 13, 2014 (doi10.1007/s1-238.014.0286.5)Google Scholar
  67. 67.
    Tan Q, et al. (2013) Erythropoiesis and pulmonary hypertension in a mouse model of human HIF2A gain of function mutation. J. Biol. Chem. 288:17134–44.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Hasegawa J, et al. (2004) Altered pulmonary vascular reactivity in mice with excessive erythrocytosis. Am. J. Respir. Crit. Care Med. 169:829–35.CrossRefPubMedGoogle Scholar
  69. 69.
    Nam S, et al. (2007) Dasatanib (BMS-354825) inhibits Stat5 signaling associated with apoptosis in chronic myelogenous leukemia cells. Mol. Cancer Ther. 6:1400–5.CrossRefPubMedGoogle Scholar
  70. 70.
    Montani D, et al. (2012) Pulmonary arterial hypertension in patients treated by dasatanib. Circulation. 125:2128–37.CrossRefGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Yang-Ming Yang
    • 1
  • Huijuan Yuan
    • 1
  • John G. Edwards
    • 2
  • Yester Skayian
    • 2
  • Kanta Ochani
    • 3
  • Edmund J. Miller
    • 3
  • Pravin B. Sehgal
    • 1
    • 4
  1. 1.Department of Cell Biology & AnatomyNew York Medical CollegeValhallaUSA
  2. 2.Department of PhysiologyNew York Medical CollegeValhallaUSA
  3. 3.Center for Heart and Lung ResearchThe Feinstein Institute for Medical ResearchManhassetUSA
  4. 4.Department of MedicineNew York Medical CollegeValhallaUSA

Personalised recommendations